Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
about
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusDistinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot StudyEffectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
P2860
Q31117903-6386A556-7242-443A-9FD1-B92BD10DE183Q33763305-E1246431-8E7D-4AE5-844D-5D7E8F09E1FEQ33871321-59445DC4-14F5-46F8-8362-461E0B1FB7CCQ37421058-BCBB1521-91F7-49C3-9F8E-3DDDA0E54154Q40091881-B3156BB6-5652-41BB-BC88-E11641030034Q41259429-18D4B45A-FB9B-4351-BEBA-FA6A42C9897AQ47109328-1A1D5770-FFD5-4DB7-A8CD-B7F4A97CFED6Q47398293-B793F330-762D-4E45-BB00-06F52CBF1010Q47995019-2233195F-2046-4167-ACD3-C9B405FECE0B
P2860
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@en
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@nl
type
label
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@en
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@nl
prefLabel
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@en
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of ipragli ...... ve randomized clinical trials.
@en
P2093
Atsunori Kashiwagi
Eiji Ueyama
Hayato Satomi
Hideyuki Takahashi
Ichiro Nakamura
Kenichi Kazuta
Kosei Kawamuki
Satoshi Yoshida
Yoshinori Kosakai
P2860
P304
P356
10.1111/JDI.12471
P577
2015-12-30T00:00:00Z